A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

August 10, 2022

Study Completion Date

August 10, 2022

Conditions
Arthritis, Rheumatoid
Interventions
OTHER

Placebo

Placebo infusion will be administered intravenously.

DRUG

Nipocalimab

Nipocalimab infusions will be administered intravenously.

Trial Locations (28)

15006

Hosp Univ A Coruna, A Coruña

15706

Hosp. Clinico Univ. de Santiago, Santiago de Compostela

20095

Hamburger Rheuma Forschungszentrum II, Hamburg

28210

DJL Clinical Research, PLLC, Charlotte

29486

Low Country Rheumatology PA, Summerville

36214

Hosp. Do Meixoeiro, Vigo

38305

West Tennessee Research Institute, Jackson

40878

Rheumazentrum Ratingen, Ratingen

41009

Hosp. Virgen Macarena, Seville

45377

STAT Research, Inc., Vandalia

48013

Hosp. Univ. de Basurto, Bilbao

75150

Southwest Rheumatology Research LLC, Mesquite

77089

Accurate Clinical Research, Inc., Houston

85210

Arizona Arthritis & Rheumatology Research, PLLC, Mesa

85306

Arizona Arthritis & Rheumatology Associates PC, Glendale

85704

Arizona Arthritis & Rheumatology Research, PLLC, Tucson

91786

Inland Rheumatology Clinical Trials, Inc., Upland

92064

Arthritis Care and Research Center Inc.: Smitha Reddy, MD, Poway

92108

TriWest Research Associates, LLC, San Diego

92260

Desert Medical Advances, Palm Desert

85-168

Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Bydgoszcz

05-830

NZOZ Lecznica Mak-Med sc, Nadarzyn

61 397

Prywatna Praktyka Lekarska Prof Um Dr Hab Med Pawel Hrycaj, Poznan

03 291

Centrum Medyczne AMED Targowek, Warsaw

EH4 2XU

Western General Hospital, Edinburgh

SE5 9RS

Kings College Hospital NHS Trust, London

NE29 8NH

North Tyneside General Hospital, Newcastle

ST6 7AG

Haywood Hospital, Stoke-on-Trent

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04991753 - A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter